European Commission approves NewAmsterdam’s Ubeslo and Evlarco in EU
The European Commission approved Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination) for NewAmsterdam Pharma and Menarini, supported by Phase 3 BROADWAY, BROOKLYN and TANDEM trials showing LDL-C reductions and favorable tolerability.